Entrada Therapeutics, Inc. (TRDA)
|52 Week Range||5.12-24.38|
|1y Target Est||-|
|DCF Unlevered||TRDA DCF ->|
|DCF Levered||TRDA LDCF ->|
|Debt / Equity||18.58%||Neutral|
Upgrades & Downgrades
Latest TRDA news
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
9 December 2022
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.
Entrada Therapeutics shares jump on collaboration with Vertex
8 December 2022
Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. VRTX, +1.85% that aims to develop trea...
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
30 August 2022
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap...
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
6 July 2022
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap...
Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday
7 June 2022
We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halte...
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
1 June 2022
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap...
5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Compan...
18 April 2022
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >